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Identity 
Other names: FLJ14651, KChAP, ZMIZ5 




The gene codes for a protein of the PIAS family 
(protein inhibitor of activated STAT (signal transducer 
and activator of transcription)). PIAS3 regulates the 
activity of several transcription factors by direct 
protein-protein interaction. Further, PIAS3 is a SUMO 
(small ubiquitin-like modifier)- 
E3 ligase, catalyzing the covalent, post-translational 
modification of specific target proteins with SUMO. 
Different splice variants of PIAS3 have been identified 
but the full-length sequence of some of these variants 
has not been described. 
Description 
The human PIAS3 gene is 10559 bp long and consists 
of 14 exons and 13 introns. 
Transcription 
Transcript length 2902 bp (CDS 1887 bp ; residues 628 
aa). 
Pseudogene 
No pseudogene reported. 
 
Figure 1. PIAS3 gene 10559 bp. Exons 1 to 14 (UTR in white, coding sequence in red) Exon 1: 1-115 (5'UTR: 1-91); Exon 2: 2075-2492; 
Exon 3: 2650-2734; Exon 4: 2963-3013; Exon 5: 3255-3345; Exon 6: 4201-4335; Exon 7: 4518-4623; Exon 8: 5195-5268; Exon 9: 5417-
5577; Exon 10: 7928-8061; Exon 11: 8142-8310; Exon 12: 8495-8628; Exon 13: 8812-8849; Exon 14: 9369-10559 (3'UTR: 9636-10559). 
 
Figure 2. The schematic domain structure of human PIAS3 protein is shown. SAP domain: nuclear localization and binding to DNA, 
transcription factors, coregulators. PINIT: nuclear retention, transcriptional repression. SP-RING: protein-protein interactions, interacts 
with the SUMO conjugase Ubc9, sumoylation. SIM: binding to SUMO. S/T: variable region, binding to coactivators. 
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Protein 
Description 
The human PIAS3 protein is a E3 SUMO-protein ligase 
consisting of 628 amino acids. It contains 5 conserved 
regions, the SAP, PINIT, SP-RING, SIM and S/T 
domains (figure 2). 
Expression 
PIAS3 is ubiquitously expressed. 
Localisation 
Nuclear as well as cytoplasmic localization. 
Function 
PIAS3 belongs to the mammalian protein inhibitor of 
activated STAT (PIAS) protein family, originally 
identified as cytokine-induced inhibitors of the STAT 
family of transcription factors. This protein class, 
referred to as SUMO-E3 ligases, increases the 
efficiency of SUMO conjugation. SUMO, a small 
ubiquitin-like modifier protein, is conjugated to a large 
number of cellular target proteins. Similar to enzymatic 
ubiquitination, the conjugation of specific SUMO 
proteins (SUMO-1-SUMO-3) to target proteins 
requires an E1-activating enzyme (Aos1/Uba2) as well 
as an E2-type SUMO-1-conjugating enzyme (Ubc9). 
Similar to many ubiquitin E3 ligases, these proteins 
contain a putative RING finger-like structure (SP-
RING, figure 2), which is essential for their SUMO-E3 
ligase activities toward various target proteins. 
Sumoylation is a dynamic process with highly diverse 
outcomes, ranging from changes in subcellular 
localization, signal transduction, transcriptional 
regulation to altered activity and stability of the 
modified protein. PIAS3 do, however, not only operate 
as SUMO-E3, since its coregulator effects are often 
independent of its RING-finger like domain but 
dependent on its capability to interact with sumoylated 
proteins via its conserved SIM (SUMO-interacting 
motif) or SAP (scaffold attachment factor-
A/B/acinus/PIAS) domain (figure 2). Beside the N-
terminal SAP, the SIM and the RING-type zinc-binding 
domain, a PINIT motif, and a serine/ threonine-rich C-
terminal region (S/T) is conserved in PIAS3 (figure 2). 
PIAS3 is involved in cytoplasmic regulation, such as 
functional interaction of PIAS3 with metabotropic 
glutamate receptor-8, voltage-gated potassium channel 
Kv1.5 and pyruvate kinase subtype M2, but the 
majority of so far reported interactions of the PIAS3 
protein occurred with transcription factors or other 
proteins linked to nuclear regulation. PIAS3 can act in 
both transcriptional repression and activation. PIAS3 
has been shown to repress STAT3 and Stat5 dependent 
transcriptional activation by blocking the DNA- 
binding of the factor without influencing its 
sumoylation. It interacts with and promotes 
sumoylation of the photoreceptor-specific transcription 
factor Nr2e3 when bound to specific promoters, which 
converts the factor to a transcriptional repressor. 
Moreover, PIAS3 was described as a repressor of 
microphthalmia transcription factor (MITF) and it was 
shown that PIAS3 blocks NF-kB mediated 
transcriptional activation by interacting with the 
p65/RelA subunit. Repression of IRF1-mediated 
transcription by PIAS3 has also been shown. PIAS3 
has been shown to activate transcription mediated by 
Smad proteins through forming a complex with Smads 
and coactivator p300/CBP; moreover, PIAS proteins 
enhance steroid receptor-dependent transcription 
through an SP-RING-mediated interaction and 
sumoylation of the coactivator protein GRIP1/SCR2. 
Finally, PIAS3 was shown to modulate the ability of 
TIF2 to mediate ligand-enhanced transcription 
activation positively or negatively, for different steroid 
receptors. 
Homology 
The mammalian PIAS family consists of seven 
structurally related proteins (PIAS1, PIAS3, PIAS3b, 
PIASxa, PIASxb, PIASy, and PIASyE6) encoded by 
four genes. PIAS orthologs are found in nonvertebrate 




PIAS3 is expressed in normal prostate and in prostate 
cancer cells and has been shown to modulate the 
transcriptional activity of androgen receptor in prostate 
cancer cells. Moreover, PIAS3 (KChAP) induces 
increased K+ efflux and apoptosis in prostate cancer 
lines. 
Glioblastoma multiforme (GBM) 
Oncogenesis 
The activation of STATs and loss of their natural 
inhibitors SOCS and PIAS is common in various 
human cancers. STAT3, a cytoplasmic transcription 
factor that becomes activated in response to a variety of 
cytokines and growth factors is aberrantly activated in 
GBM tumors. STAT3 activation correlates with 
strongly reduced PIAS3 protein expression in GBM 
tissues. Inhibition of PIAS3 resulted in enhanced 
glioblastoma cellular proliferation, and, conversely, 
PIAS3 overexpression inhibits STAT3 transcriptional 
activity, expression of STAT3-regulated genes, and cell 
proliferation. This suggests that the loss of PIAS3 in 
GBM contributes to enhanced STAT3 transcriptional 
activity and subsequent cell proliferation. 
Melanoma 
Oncogenesis 
PIAS3 functions as a key molecule in suppressing the 
transcriptional activity of both MITF and STAT3, two 
transcription factors that play a major role in the 
development, proliferation and survival of mast cells 
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and melanocytes. In addition to its role in normal cell 
signaling, constitutively activated STAT3 signaling 
directly contributes to oncogenesis in many human 
cancers. STAT3 cooperates with MITF in the induction 
of cellular transformation. Evidence was provided 
suggesting that PIAS3 halt proliferation and induce 
apoptotic cell death in mast cells and in melanoma cells 
by inhibiting the transcriptional activity of the two 
oncogenic factors MITF and STAT3. Therefore PIAS3 
may play a role in tumor suppression by inhibiting 
oncogenic processes induced by STAT3 and MITF. 
Non-small cell lung cancer (NSCLC) 
Disease 
The Epidermal Growth Factor Receptor (EGFR)-
STAT3 axis plays an important role in oncogenic 
signaling of non-small cell lung cancer (NSCLC). The 
negative regulator of STAT3-mediated transcriptional 
activation, PIAS3, was shown to modulate oncogenic 
EGFR-STAT3 signaling in lung cancer. 
Overexpression of PIAS3 decreases STAT3 
transcriptional activity and proliferation of NSCLC 
cells and when used in conjunction with EGFR 
inhibitors, further increased the anti-proliferative 
effects. This suggests that PIAS3 acts as an inhibitor of 
EGFR-STAT3 induced oncogenic action. 
To be noted 
Note 
TAR syndrome (Thrombocytopenia-absent radius) is a 
rare genetic disorder characterized by low platelet 
counts and bilateral radial aplasia. TAR is also 
frequently associated with cardiac abnormalities and 
cow's milk intolerance. In 2007 a research article 
described a common microdeletion of 200 kb on 
chromosome 1q21.1 in patients with TAR syndrome. 
PIAS3 is one of 11 genes encompassed by this 
microdeletion. 
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